Literature DB >> 11705901

Role of the classical pathway of complement activation in experimentally induced polymicrobial peritonitis.

I Celik1, C Stover, M Botto, S Thiel, S Tzima, D Künkel, M Walport, W Lorenz, W Schwaeble.   

Abstract

The complement system and the natural antibody repertoire provide a critical first-line defense against infection. The binding of natural antibodies to microbial surfaces opsonizes invading microorganisms and activates complement via the classical pathway. Both defense systems cooperate within the innate immune response. We studied the role of the complement system in the host defense against experimental polymicrobial peritonitis using mice lacking either C1q or factor B and C2. The C1q-deficient mice lacked the classical pathway of complement activation. The factor B- and C2-deficient mice were known to lack the classical and alternative pathways, and we demonstrate here that these mice also lacked the lectin pathway of complement activation. Using inoculum doses adjusted to cause 42% mortality in the wild-type strain, none of the mice deficient in the three activation routes of complement (factor B and C2 deficient) survived (mortality of 100%). Mortality in mice deficient only in the classical pathway of complement activation (C1q deficient) was 83%. Application of further dilutions of the polymicrobial inoculum showed a dose-dependent decrease of mortality in wild-type controls, whereas no changes in mortality were observed in the two gene-targeted strains. These results demonstrate that the classical activation pathway is required for an effective antimicrobial immune defense in polymicrobial peritonitis and that, in the infection model used, the remaining antibody-independent complement activation routes (alternative and lectin pathways) provide a supporting line of defense to gain residual protection in classical pathway deficiency.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11705901      PMCID: PMC98815          DOI: 10.1128/IAI.69.12.7304-7309.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  37 in total

Review 1.  Does properdin crosslink the cellular and the humoral immune response?

Authors:  W J Schwaeble; K B Reid
Journal:  Immunol Today       Date:  1999-01

Review 2.  Evolving strategies in the treatment of sepsis and systemic inflammatory response syndrome (SIRS).

Authors:  K D Horn
Journal:  QJM       Date:  1998-04

3.  Human L-ficolin: plasma levels, sugar specificity, and assignment of its lectin activity to the fibrinogen-like (FBG) domain.

Authors:  Y Le; S H Lee; O L Kon; J Lu
Journal:  FEBS Lett       Date:  1998-03-27       Impact factor: 4.124

4.  Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies.

Authors:  M Botto; C Dell'Agnola; A E Bygrave; E M Thompson; H T Cook; F Petry; M Loos; P P Pandolfi; M J Walport
Journal:  Nat Genet       Date:  1998-05       Impact factor: 38.330

5.  A targeted disruption of the murine complement factor B gene resulting in loss of expression of three genes in close proximity, factor B, C2, and D17H6S45.

Authors:  P R Taylor; J T Nash; E Theodoridis; A E Bygrave; M J Walport; M Botto
Journal:  J Biol Chem       Date:  1998-01-16       Impact factor: 5.157

6.  IgG and complement-mediated tissue damage in the absence of C2: evidence of a functionally active C2-bypass pathway in a guinea pig model.

Authors:  E Wagner; J L Platt; D N Howell; H C Marsh; M M Frank
Journal:  J Immunol       Date:  1999-09-15       Impact factor: 5.422

7.  Impaired mast cell-dependent natural immunity in complement C3-deficient mice.

Authors:  A P Prodeus; X Zhou; M Maurer; S J Galli; M C Carroll
Journal:  Nature       Date:  1997-11-13       Impact factor: 49.962

8.  T cell-dependent immune response in C1q-deficient mice: defective interferon gamma production by antigen-specific T cells.

Authors:  A J Cutler; M Botto; D van Essen; R Rivi; K A Davies; D Gray; M J Walport
Journal:  J Exp Med       Date:  1998-06-01       Impact factor: 14.307

9.  Protection from lethal gram-positive infection by macrophage scavenger receptor-dependent phagocytosis.

Authors:  C A Thomas; Y Li; T Kodama; H Suzuki; S C Silverstein; J El Khoury
Journal:  J Exp Med       Date:  2000-01-03       Impact factor: 14.307

10.  A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection.

Authors:  M Boes; A P Prodeus; T Schmidt; M C Carroll; J Chen
Journal:  J Exp Med       Date:  1998-12-21       Impact factor: 14.307

View more
  18 in total

1.  Distinct different contributions of the alternative and classical complement activation pathway for the innate host response during sepsis.

Authors:  Katja Dahlke; Christiane D Wrann; Oliver Sommerfeld; Maik Sossdorf; Peter Recknagel; Svea Sachse; Sebastian W Winter; Andreas Klos; Gregory L Stahl; Yuanyuan Xu Ma; Ralf A Claus; Konrad Reinhart; Michael Bauer; Niels C Riedemann
Journal:  J Immunol       Date:  2011-01-24       Impact factor: 5.422

2.  The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice.

Authors:  Jeremy S Brown; Tracy Hussell; Sarah M Gilliland; David W Holden; James C Paton; Michael R Ehrenstein; Mark J Walport; Marina Botto
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-11       Impact factor: 11.205

3.  Involvement of the lectin pathway of complement activation in antimicrobial immune defense during experimental septic peritonitis.

Authors:  Michaela Windbichler; Bernd Echtenacher; Thomas Hehlgans; Jens C Jensenius; Wilhelm Schwaeble; Daniela N Männel
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

4.  Dependence of positive effects of granulocyte colony-stimulating factor on the antibiotic regimen: evaluation in rats with polymicrobial peritonitis.

Authors:  Artur Bauhofer; Alexander Torossian; Wilfried Lorenz; Martin Middeke; Ulrike Plaul; Philipp Schütz; Benno Stinner; Markus Hattel; Ilhan Celik
Journal:  World J Surg       Date:  2004-08-03       Impact factor: 3.352

5.  Role for the alternative complement pathway in ischemia/reperfusion injury.

Authors:  Gregory L Stahl; Yuanyuan Xu; Liming Hao; Mendy Miller; Jon A Buras; Michael Fung; Hui Zhao
Journal:  Am J Pathol       Date:  2003-02       Impact factor: 4.307

6.  Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine.

Authors:  Ioanna Skountzou; Maria del Pilar Martin; Baozhong Wang; Ling Ye; Dimitrios Koutsonanos; Will Weldon; Joshy Jacob; Richard W Compans
Journal:  Vaccine       Date:  2009-08-03       Impact factor: 3.641

7.  Impaired opsonization with C3b and phagocytosis of Streptococcus pneumoniae in sera from subjects with defects in the classical complement pathway.

Authors:  Jose Yuste; Ashwin Sen; Lennart Truedsson; Göran Jönsson; Liang-Seah Tay; Catherine Hyams; Helen E Baxendale; Fiona Goldblatt; Marina Botto; Jeremy S Brown
Journal:  Infect Immun       Date:  2008-06-09       Impact factor: 3.441

8.  Dietary exposure of 17-alpha ethinylestradiol modulates physiological endpoints and gene signaling pathways in female largemouth bass (Micropterus salmoides).

Authors:  Reyna-Cristina Colli-Dula; Christopher J Martyniuk; Kevin J Kroll; Melinda S Prucha; Marianne Kozuch; David S Barber; Nancy D Denslow
Journal:  Aquat Toxicol       Date:  2014-08-27       Impact factor: 4.964

9.  Heavily isotype-dependent protective activities of human antibodies against vaccinia virus extracellular virion antigen B5.

Authors:  Mohammed Rafii-El-Idrissi Benhnia; Megan M McCausland; John Laudenslager; Steven W Granger; Sandra Rickert; Lilia Koriazova; Tomoyuki Tahara; Ralph T Kubo; Shinichiro Kato; Shane Crotty
Journal:  J Virol       Date:  2009-09-30       Impact factor: 5.103

10.  Complement-dependent injury and protection in a murine model of acute dextran sulfate sodium-induced colitis.

Authors:  Jennifer Schepp-Berglind; Carl Atkinson; Michelle Elvington; Fei Qiao; Peter Mannon; Stephen Tomlinson
Journal:  J Immunol       Date:  2012-05-07       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.